Illumina (ILMN)
(Real Time Quote from BATS)
$112.34 USD
-2.12 (-1.85%)
Updated May 17, 2024 12:24 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Illumina, Inc. [ILMN]
Reports for Purchase
Showing records 341 - 360 ( 361 total )
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Pullback Creates Opportunity to Own NGS Leader - Upgrading to Buy and Reiterating $75 PT
Provider: AURIGA USA
Analyst: MEHRA R
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Buyers on Recent Selloff & Closure of Note Offering; Fears of Large Dilutive Deal Unrealistic
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
PACB 4Q10 Highlights; Timelines, Specs on Track; 150k Upgrade Begun; Co. Indicating Readlength Headroom
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
No 4Q10 Surprises; Sequencing Business Dominating; GMs Tolerable & OpEx Fine; Reaffirming OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
4Q10 Results Review: Solid Quarter; But Closing In On Our Price Target; Downgrade to Hold
Provider: AURIGA USA
Analyst: MEHRA R
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
4Q10 Preview; Juicy Announcements Unlikely; Excited by HiSeq Consumables & MiSeq; Admitting Defeat with Prior Multiple;
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Repeats Best-in-Show at JPM; Positive 4Q10 Rev Preannouncement
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Releases 4Q10 Results and Preliminary 2011 Guidance; Updates Pipeline Progress.
Provider: AURIGA USA
Analyst: MEHRA R
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Broadening Applications and Customer Base Bode Well; Raising Price Target to $75.
Provider: AURIGA USA
Analyst: MEHRA R
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Strong 3Q10 Across the Board; Acceleration in Genotyping Surprises; Sequencing Solid as Ever; Eclipsing 2010 Guidance
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Strong Upgrade Cycle and Broadening Customer Base; Increasing Price Target to $60.
Provider: AURIGA USA
Analyst: MEHRA R
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Pacific Biosciences Cost Per Genome Sensitivity Analysis; Accuracy and Actual Cost Per Genome Unclear from IPO Roadshow Chatter
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage of ILMN with an OUTPERFORM Rating and $60 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Strong Quarter and Robust Guidance.
Provider: AURIGA USA
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Robust Quarter; Reiterating Buy
Provider: AURIGA USA
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Reported Q4 and Guidence for 2010 in line with Preannounced Numbers
Provider: AURIGA USA